Generic Name: regorafenib

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Bayer

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Stivarga is a multikinase inhibitor approved for metastatic colorectal cancer, advanced or metastatic gastrointestinal stromal tumor (GIST) and liver cancer previously treated with Nexavar (sorafenib).

General Info

Stivarga is a kinase inhibitor that blocks the action of several enzymes, including VEGFR, PDGFR, BRAF, KIT and RET, that play a role in cell growth and development of blood vessels that feed tumors.

The CORRECT trial showed that Stivarga delays disease progression and improves survival in people with colorectal cancer. The GRID trial found that it improved progression-free survival in people with GIST. The RESOURCE trial showed Stivarga improved progression-free and overall survival in people with liver cancer. It was first approved in 2012.


Dosing Info: Stivarga is taken as a once-daily pill with a low-fat meal. It is usually taken for three weeks followed by a week off.

Side Effects

Common side effects include abdominal pain, fatigue, diarrhea, nausea, loss of appetite, weight loss, high blood pressure and skin rash. Potential serious side effects may include severe bleeding (hemorrhage), severe hypertension, severe skin reactions, blocked blood flow to the heart, stomach or intestinal perforation and increased risk of infections and slow wound healing. The Stivarga label includes a warning about severe liver toxicity. Stivarga may cause fetal harm if used during pregnancy.

For More Info:

Patient Assistance Program Info:

Last Reviewed: December 15, 2018